Antibody-drug Conjugate Information
General Information of This Antibody-drug Conjugate (ADC)
| ADC ID |
DRG0FWMPN
|
|||||
|---|---|---|---|---|---|---|
| ADC Name |
YL202
|
|||||
| Synonyms |
YL 202; YL-202
Click to Show/Hide
|
|||||
| Organization |
Mersana Therapeutics, Inc.Suzhou Medilink Therapeutics Ltd.
|
|||||
| Drug Status |
Phase 1
|
|||||
| Indication |
In total 3 Indication(s)
Breast cancer [ICD11:2C60-2C65]
Phase 1
Metastatic breast cancer [ICD11:2C6Y]
Phase 1
Non-small cell lung cancer [ICD11:2C25]
Phase 1
|
|||||
| Antibody Name |
Undisclosed
|
|||||
| Antigen Name |
Tumor-associated calcium signal transducer 2 (TACSTD2)
|
Antigen Info | ||||
| Payload Name |
Undisclosed
|
|||||
| Linker Name |
Undisclosed
|
|||||
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.